TLSI

TriSalus Life Sciences, Inc. NASDAQ Listed Feb 8, 2021

Healthcare ·Medical - Devices ·US · trisaluslifesci.com

$4.46

Mkt Cap $169.1M

52w Low $3.42 23.0% of range 52w High $7.95

50d MA $4.37 200d MA $4.99

P/E (TTM) -2.4x

EV/EBITDA -10.3x

P/B —

Debt/Equity -1.0x

ROE 115.9%

P/FCF -14.0x

RSI (14) —

ATR (14) —

Beta 0.54

50d MA $4.37

200d MA $4.99

Avg Volume 182.1K

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

SIC Code

3841

CIK (SEC)

1826667

Phone

888 321 5212

6272 West 91st Avenue · Westminster, CO 80031 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	AMC	-0.13	-0.12	+7.7%	4.77	-1.5%	-6.3%	-3.1%	-10.7%	-12.8%	-14.0%	—
Nov 13, 2025	AMC	-0.17	-0.96	-464.7%	4.39	-6.8%	+3.9%	+2.1%	+4.8%	+4.3%	+13.0%	—
Aug 12, 2025	AMC	-0.22	-0.27	-22.7%	3.65	+3.8%	+8.2%	+6.3%	+24.7%	+33.2%	+27.4%	—
May 15, 2025	AMC	-0.20	-0.33	-65.0%	5.11	+2.0%	+0.6%	+1.4%	+5.1%	+6.5%	+4.7%	—
Mar 27, 2025	AMC	-0.35	-0.35	+0.0%	5.50	+1.3%	+2.2%	+0.4%	+0.0%	+0.5%	-5.1%	—
Nov 14, 2024	AMC	-0.36	-0.40	-11.1%	4.01	-4.7%	-2.0%	-8.5%	+2.7%	+1.5%	+10.5%	—
Aug 14, 2024	AMC	-0.49	-0.21	+57.1%	5.85	-2.9%	+0.7%	-1.7%	-2.6%	-4.6%	-5.3%	—
May 15, 2024	AMC	-0.65	-0.54	+16.9%	9.39	+1.2%	+3.3%	+4.9%	+8.1%	+6.2%	+3.1%	—
Feb 27, 2024	AMC	—	-1.34	—	9.22	-0.8%	+2.6%	+3.5%	+1.1%	+6.6%	+7.3%	—
Nov 14, 2023	AMC	—	-0.13	—	4.00	+2.5%	-2.0%	-1.2%	-4.5%	-6.8%	-6.8%	—
Jun 30, 2023	AMC	—	-0.53	—	10.48	+0.2%	+0.2%	+0.0%	+0.3%	+0.3%	+0.3%	—
Mar 31, 2023	AMC	—	-0.31	—	10.20	+1.3%	+0.9%	+1.5%	+1.5%	+0.0%	+0.1%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 9	Canaccord Genuity	Maintains	Buy → Buy	—	$4.47	$4.33	-3.1%	+3.4%	-4.7%	-6.9%	-8.3%	-8.7%
Mar 6	Canaccord Genuity	Maintains	Buy → Buy	—	$4.77	$4.70	-1.5%	-6.3%	-3.1%	-10.7%	-12.8%	-14.0%
Dec 17	Canaccord Genuity	Maintains	Buy → Buy	—	$7.42	$7.39	-0.4%	-1.6%	-1.9%	+0.0%	+0.5%	-5.0%
Mar 28	Canaccord Genuity	Maintains	Buy → Buy	—	$5.50	$5.57	+1.3%	+2.2%	+0.4%	+0.0%	+0.5%	-5.1%
Jan 24	Roth MKM	Maintains	Buy → Buy	—	$5.16	$5.16	+0.0%	+0.4%	+2.7%	-3.7%	-5.2%	-1.0%
Nov 15	Canaccord Genuity	Maintains	Buy → Buy	—	$4.01	$3.82	-4.7%	-2.0%	-8.5%	+2.7%	+1.5%	+10.5%
Jun 27	Canaccord Genuity	Maintains	Buy → Buy	—	$5.65	$5.90	+4.4%	+1.9%	-2.3%	-5.7%	-10.4%	-1.9%

Data updated apr 27, 2026 5:00am · Source: massive.com